Resonetics

Medtronic exists to solve the world's most challenging health problems through bold innovation and advanced technology. For over 75 years, the company has pioneered groundbreaking health tech that transforms lives, treating more than 70 conditions across the human body - from heart failure to Parkinson's disease. As a global leader in healthcare technology, Medtronic leverages data, AI, and cutting-edge therapies to address complex healthcare challenges that affect millions of people worldwide. With 95,000 employees across 150 countries, the company's mission-driven approach combines medical expertise with technological innovation to restore health, extend life, and alleviate pain for patients everywhere. From its humble beginnings in a Minneapolis garage to becoming the world's largest medical technology company, Medtronic continues to push boundaries and redefine what's possible in healthcare, making a meaningful impact on global health outcomes every day through innovations that put more life into patients' years.

At Fortive, we believe that anything is possible when people come together to solve problems no single individual could solve alone. Our global team of 10,000 is united by a powerful continuous improvement mindset that transcends borders and time zones. We're a collection of forward-looking companies where engineers, scientists, and problem-solvers drive innovation in industrial safety, healthcare sterilization, and predictive maintenance - using our proven Fortive Business System to accelerate positive impact. We thrive on collaboration and inclusive culture that empowers everyone to grow. We believe in you - your potential to learn, develop, and make a difference. We believe in us - the collective strength of our diverse teams tackling mission-critical challenges. We believe in growth - being honest about what's working and what isn't, and never stopping in our pursuit of excellence. From our headquarters in Everett, Washington to operations spanning 50 countries, Fortive team members embrace a growth mindset and take ownership of delivering essential technologies that make our world safer and more productive.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. The company’s work centers on degrading proteins - 'Degrading Proteins, Making Medicines' - and advancing precision approaches that target undruggable or inadequately drugged proteins with unprecedented specificity. On its website, the team is described as combining expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics. Monte Rosa’s QuEEN
9 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is described as using AI-guided chemistry alongside diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs. The company positions this platform as enabling access to a wide-ranging, differentiated target space across multiple therapeutic areas, and references advancing multiple MGD programs through its pipeline. The company is headquartered in Boston, Massachusetts, and also lists a Basel, Switzerland location on its site.

We're a global team dedicated to improving well-being through hygiene and health solutions. Every day, we care for about a billion people across 150 countries, developing products that are essentials in everyday life. Our expertise stretches back decades, but we've been Essity since 2017 when we became an independent company focused on breaking barriers to well-being. What drives us is the belief that hygiene and health are fundamental to human dignity and quality of life. We operate across three business areas - Health & Medical, Consumer Goods, and Professional Hygiene - with brands like TENA, Tork, Libresse, and Leukoplast that you probably know. We're constantly working on innovations that make a real difference, from products that help people manage incontinence with confidence to sustainable solutions that reduce our environmental footprint. Sustainability isn't an afterthought for us; it's woven into how we do business, with ambitious targets including net zero emissions by 2050.

In 1999, two science-based companies with shared visions came together to form AstraZeneca: Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined decades of pharmaceutical expertise, creating a global powerhouse uniquely positioned to push the boundaries of scientific discovery. What began as a union of strengths has evolved into a relentless pursuit of breakthrough therapies, with the company investing billions annually in research and development to transform patient outcomes across oncology, biopharmaceuticals, respiratory, and rare diseases. Today, AstraZeneca stands at the forefront of precision medicine and next-generation therapeutics, harnessing the power of data science, AI, and innovative technologies like cell therapies. With 197 projects in the pipeline and 16 blockbuster medicines, the company operates from six strategic R&D centres spanning Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai, and Beijing. Their bold aspiration to deliver 20 new medicines by 2030 reflects an unwavering commitment to following the science and putting patients first - values that have driven every decision since that pivotal merger more than two decades ago.

Armtec Defense Technologies designs and manufactures combustible ordnance, infrared decoy flares, radar countermeasure chaff, and other pyrotechnic devices for the U.S. Department of Defense and allied nations. The company operates three dedicated production facilities across the United States: combustible ordnance is produced in Coachella, California; infrared decoy flares in East Camden, Arkansas; and radar countermeasure chaff in Lillington, North Carolina. Armtec is an operating unit of TransDigm Group and holds ISO 9001:2015 certification. The company's workforce spans scientists, engineers, and operators, with a stated culture built on open communication, trust, and teamwork. Safety, quality, and environmental responsibility are central to its operating principles. Armtec describes its product line as the largest and most varied in the combustible ordnance and expendable countermeasure industries. For veterans considering a transition into defense manufacturing, Armtec's mission is directly aligned with military operational readiness. Its work - producing the decoy flares, radar chaff, and ordnance used by U.S. and allied forces - sits at the intersection of technical manufacturing and national security. The disciplined, safety-first environment and team-oriented culture reflect operational values familiar to those with military backgrounds.